Skip to main content
SANA
NASDAQ Life Sciences

Sana Biotechnology Secures Mayo Clinic Partnership & $25M Investment, Reports Positive Clinical Data

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$3.592
Mkt Cap
$950.046M
52W Low
$1.6
52W High
$6.55
52W Position info
125% above low
Off High info
45% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

SANA has more than doubled off its 52-week low of $1.6.

Summary

Sana Biotechnology reported its first-quarter 2026 financial results and provided significant business updates. The company announced a strategic collaboration with Mayo Clinic to advance its SC451 program for type 1 diabetes, which includes an approximately $25 million equity investment from Mayo Clinic. Additionally, Sana shared updated positive 14-month clinical results from an investigator-sponsored trial of UP421, demonstrating survival and function of pancreatic beta cells without immunosuppression in a type 1 diabetes patient. The company also highlighted continued progress towards initiating Phase 1 trials for SC451 and SG293 later this year, and reported a cash position of $101.1 million, with a pro forma $128.9 million including the Mayo investment and recent ATM activity, providing a cash runway into 2027. These developments, particularly the Mayo Clinic partnership and positive clinical data, are highly material for a biotech company, signaling strong validation and pipeline advancement. Traders will be watching for further clinical trial initiations and data readouts.

At the time of this announcement, SANA was trading at $3.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $950M. The 52-week trading range was $1.60 to $6.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

SANA - Latest Insights

SANA
Nov 05, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.44
Real-time Price: $1.64 info
Change: -$0.8014 (-33%) info
Market Cap: $476.42M info
SANA
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $1.64 info
Change: -$0.7714 (-32%) info
Market Cap: $476.42M info
SANA
Sep 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.85
Real-time Price: $1.64 info
Change: -$2.21 (-57%) info
Market Cap: $476.42M info
SANA
Aug 10, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.53
Real-time Price: $1.64 info
Change: -$1.89 (-54%) info
Market Cap: $476.42M info
SANA
Aug 10, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.53
Real-time Price: $1.64 info
Change: -$1.89 (-54%) info
Market Cap: $476.42M info